Champions Biotechnology, Inc.

Type: Public
On the web: http://www.championsbiotechnology.com
Employees: 11
Employee growth: 175.0%

Champions Biotechnology is hoping to win big in the field of cancer research. In 2007 the company acquired two anticancer drugs, as well as a preclinical platform for studying them. Its Biomerk Tumorgrafts platform allows the company to implant human tumors of various cancer types into mice, allowing scientists to study the effects of investigational drugs on human cancers. The company uses the platform in its own research and also provides tumor-specific research to doctors, as well as the Tumorgraft platform to other drug developers. The company intends to develop its internal drug candidates through preclinical stages and enlist the help of larger pharmaceutical partners to continue development.

Key numbers for fiscal year ending April, 2009:
Sales: $3.7M
One year growth: 165.0%
Net income: ($2.2)M

Officers:
Chairman: David Sidransky
President: Douglas D. Burkett
CFO: Mark R. Schonau

Competitors:
Amgen
Bristol-Myers Squibb
Genentech